OSI-906 (Linsitinib)

Catalog No.S1091

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

OSI-906 (Linsitinib) Chemical Structure

OSI-906 (Linsitinib) Chemical Structure
Molecular Weight: 421.49

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

IGF-1R Inhibitors with Unique Features

  • Pan IGF-1R Inhibitor

    GSK1904529A Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • Most Potent IGF-1R Inhibitor

    BMS-754807 IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • IGF-1R Inhibitor in Clinical Trial

    BMS-754807 Phase II for Breast Cancer.

  • Newest IGF-1R Inhibitor

    PQ 401 Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Product Information

  • Compare IGF-1R Inhibitors
    Compare IGF-1R Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)

 View  More

IC50 35 nM 75 nM 75 nM >10 μM
In vitro OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-FukMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XydmlEPTB;MD6wNlgxPiEQvF2=NFu5ZolUSU6JRWK=
KS-1M{fuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFThWWFKSzVyPUCuNFM5OzVizszNMYfTRW5ITVJ?
TE-11NW\qOYNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTBwMEe4NlIh|ryPNIL4O2hUSU6JRWK=
EW-1NXrmdI93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jsNWlEPTB;MD6wPFU5PSEQvF2=MV\TRW5ITVJ?
HMV-IIM1HrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjpVWs4UUN3ME2wMlA5QDR4IN88US=>M2npW3NCVkeHUh?=
COLO-205NH\QOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTBwMUC0OVQh|ryPMkDiV2FPT0WU
ES1M{HQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG[y[3hKSzVyPUCuNVA3QTZizszNMW\TRW5ITVJ?
GDM-1NX;jdYJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfofo5KSzVyPUCuNVM3PzJizszNMWPTRW5ITVJ?
ML-2M4HrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX[4XnVmUUN3ME2wMlE2QDl4IN88US=>NVGx[3B2W0GQR1XS
Saos-2MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTBwMU[1NlYh|ryPMnrFV2FPT0WU
NCI-H1355NF7a[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfaTWM2OD1yLkG4NVM2KM7:TR?=NYT4fFh4W0GQR1XS
G-401MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PrNGlEPTB;MD6xPFI{KM7:TR?=M2fNVnNCVkeHUh?=
EW-16NHf6ZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH:5UXJKSzVyPUCuNVg4PzdizszNNIG5S2lUSU6JRWK=
EW-7NIfk[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjiSmJKSzVyPUCuNVg5QDFizszNNHfSR4tUSU6JRWK=
NCI-H727NVXwSHFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlq1TWM2OD1yLkG5O|k1KM7:TR?=NGW0SpRUSU6JRWK=
LCLC-97TM1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\yS5FKSzVyPUCuNlA6PTVizszNNXzZ[IpVW0GQR1XS
NCI-H650MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTneJpmUUN3ME2wMlIyOzh2IN88US=>NGXS[FlUSU6JRWK=
NCI-H2122MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHX6WJRKSzVyPUCuNlMzQTlizszNNV\nVGg{W0GQR1XS
SK-N-DZNITrb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;meWFKSzVyPUCuNlM3QThizszNNFTJfFVUSU6JRWK=
HT-29NIn5bItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTBwMkSyOFgh|ryPNEOwZYNUSU6JRWK=
LB771-HNCNIjNboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvaTlhrUUN3ME2wMlI2QTF3IN88US=>MofrV2FPT0WU
HT-144NV21SplMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkT2TWM2OD1yLkK2NVkyKM7:TR?=NWX6ZnBoW0GQR1XS
LAN-6MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTBwMk[zOFgh|ryPMVfTRW5ITVJ?
EW-18M4r4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XEc2lEPTB;MD6yO|AxOSEQvF2=MXXTRW5ITVJ?
LS-1034MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIf6fVJKSzVyPUCuNlcyOzJizszNNXvQb41XW0GQR1XS
EW-11M3HKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXybHdKSzVyPUCuNlg1OzJizszNNFz0U4NUSU6JRWK=
SNU-C1NWrFbW1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLLSYhKSzVyPUCuNlk{OTNizszNMmn5V2FPT0WU
RS4-11MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zzR2lEPTB;MD6zN|c2QCEQvF2=MW\TRW5ITVJ?
ES4MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwNEGwN|gh|ryPNUnmVXRnW0GQR1XS
COLO-320-HSRNVfnPWh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLYTWM2OD1yLkSxN|Y5KM7:TR?=Mlv5V2FPT0WU
NB10M2T3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTBwNEW0N|ch|ryPMnfXV2FPT0WU
BFTC-905Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfmTWM2OD1yLkS2O|U5KM7:TR?=MlXHV2FPT0WU
A375NWDzNIJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjxfohHUUN3ME2wMlQ4PjF5IN88US=>M4mxR3NCVkeHUh?=
SJRH30NIrvZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnrTmlKSzVyPUCuOVA5OjJizszNMlrsV2FPT0WU
NOS-1MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPVTWM2OD1yLkWyNlY4KM7:TR?=NXTXbHVpW0GQR1XS
SIG-M5MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTBwNUO1OVch|ryPNX;URVN[W0GQR1XS
DOKMkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwNUW2JO69VQ>?MYnTRW5ITVJ?
NB69NGHleINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXK1XJdEUUN3ME2wMlU5OjV5IN88US=>M4jwcnNCVkeHUh?=
SK-NEP-1M2TOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHGeFBGUUN3ME2wMlYxOjN4IN88US=>M3;tUXNCVkeHUh?=
SK-MM-2MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\tUWpKSzVyPUCuOlU1QTFizszNM3jXXnNCVkeHUh?=
NCI-H358MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPxTWM2OD1yLk[3NFgzKM7:TR?=NHPFT45USU6JRWK=
RH-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTBwN{S4OVkh|ryPMVPTRW5ITVJ?
NH-12MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\vd5hKSzVyPUCuO|YxPDZizszNMkP1V2FPT0WU
TE-12NFnxUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHnTWM2OD1yLke2OFg3KM7:TR?=M2Xhe3NCVkeHUh?=
COLO-668NH\IZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTSTWM2OD1yLki0OlY3KM7:TR?=NGXSfpNUSU6JRWK=
PANC-08-13Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTBwOE[zO|ch|ryPMX7TRW5ITVJ?
HCC2998MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2POcmlEPTB;MD64PFI3OyEQvF2=MWDTRW5ITVJ?
ABC-1NYDYOZZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7qPVFKSzVyPUCuPVA{PTJizszNMYPTRW5ITVJ?
ES6NGrLVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\Y[JdKSzVyPUCuPVExPjZizszNMmLxV2FPT0WU
SNU-387NH;GdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHaeW5yUUN3ME2wMlk6Ozl|IN88US=>Ml3xV2FPT0WU
CMKM17UfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEey[VlKSzVyPUCuPVk6OjlizszNNHiwfpFUSU6JRWK=
SJSA-1NIHxeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\vOW9IUUN3ME2xMlA{PjV|IN88US=>NX;4XFQzW0GQR1XS
SIMAM3TUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTFwME[4NlUh|ryPNHr4fmJUSU6JRWK=
ES3MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{T4ZWlEPTB;MT6xNlI6PyEQvF2=MX\TRW5ITVJ?
IGROV-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTFwMUW0OFQh|ryPM3LOOHNCVkeHUh?=
MEL-JUSOMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DlUmlEPTB;MT6xOVc2QSEQvF2=M1LzXnNCVkeHUh?=
T84Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULTTJdsUUN3ME2xMlIxQTF2IN88US=>NH3xS|hUSU6JRWK=
CAL-85-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPUWY9EUUN3ME2xMlI{OTN6IN88US=>MX7TRW5ITVJ?
RDMmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULNSIRqUUN3ME2xMlI3PDV3IN88US=>Mn7UV2FPT0WU
TE-8M{XGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmToTWM2OD1zLkOxOFYzKM7:TR?=MWnTRW5ITVJ?
L-363M{L6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTFwM{SyNFgh|ryPNHHoR5NUSU6JRWK=
EKVXNXfEcmMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTzTWM2OD1zLkO0OVY5KM7:TR?=MXzTRW5ITVJ?
SK-MEL-3M4fCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvVOHBKSzVyPUGuOFg2PTZizszNNITZcWdUSU6JRWK=
TGBC24TKBNHzze2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jyNGlEPTB;MT61NFE6OyEQvF2=NFLnR4ZUSU6JRWK=
NCI-H1770M{DOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPzTWM2OD1zLkWxNVE{KM7:TR?=NVi4bXV7W0GQR1XS
HuH-7MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnUR5pKSzVyPUGuOlAxQThizszNMmDNV2FPT0WU
HL-60M2OwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvTW5JKSzVyPUGuOlY6OjhizszNMXfTRW5ITVJ?
TE-1MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWm0bnJlUUN3ME2xMlcxQTR3IN88US=>MVXTRW5ITVJ?
LC-2-adNVTRbWJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTFwN{O4PFch|ryPMWHTRW5ITVJ?
LB647-SCLCMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzhS2NTUUN3ME2xMlc3PTh|IN88US=>MkX6V2FPT0WU
NCI-H2171NHHCN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUj0[mxLUUN3ME2xMlc4PzF4IN88US=>MXTTRW5ITVJ?
SK-PN-DWNGDUdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXH5S5M6UUN3ME2xMlkyOjl6IN88US=>MnX0V2FPT0WU
MC-IXCNEiyW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHLd5VKSzVyPUGuPVg6QCEQvF2=NGDkbW9USU6JRWK=
LS-513MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zHZWlEPTB;Mj6wOVMxPSEQvF2=NGHaOnJUSU6JRWK=
EW-3MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXOTWM2OD1{LkC5PFQ1KM7:TR?=M1;nb3NCVkeHUh?=
OPM-2NV7Leo5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTJwMUCyJO69VQ>?MVTTRW5ITVJ?
LP-1NFvSdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;NTHNKSzVyPUKuNlU5ODdizszNNVHUSYhOW0GQR1XS
LU-134-AM{[wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfCWWNKSzVyPUKuNlc4KM7:TR?=NEW0c4FUSU6JRWK=
CP66-MELMnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rvXWlEPTB;Mj6yPVAyPCEQvF2=NG\hR3JUSU6JRWK=
HCC1143NIrLRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1[zNWlEPTB;Mj60OVM3QCEQvF2=M{P6cnNCVkeHUh?=
LOXIMVIM13sOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfqR4VKSzVyPUKuOlAzOSEQvF2=MWLTRW5ITVJ?
TE-10NFvX[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV2wT|duUUN3ME2yMlcxQDN6IN88US=>MYrTRW5ITVJ?
NCI-H1882M1zMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4X2cGlEPTB;Mj63OVIzPyEQvF2=MlzsV2FPT0WU
CHP-126MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HSc2lEPTB;Mj63OlMyPyEQvF2=MUnTRW5ITVJ?
NCI-H1623NX;ZT4x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFX4ZWtKSzVyPUKuPVIxOjRizszNNGf1coJUSU6JRWK=
GB-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnyXmFtUUN3ME2yMlk{PDB2IN88US=>NX3Vd5hOW0GQR1XS
RCC10RGBNXnHS|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPGcVNKSzVyPUKuPVUzQDFizszNNXHyfoNQW0GQR1XS
NCI-H2141NVPhU2Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvPTWM2OD1{Lkm2PFk3KM7:TR?=MoHWV2FPT0WU
GI-ME-NMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;iemlEPTB;Mz6wNFU3PSEQvF2=M2S0fXNCVkeHUh?=
NCI-H526M{\Jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjoXJlKSzVyPUOuNFQxQDVizszNNXTDNGRpW0GQR1XS
NCI-H747M{HpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HF[mlEPTB;Mz6wOFk6OiEQvF2=M164SnNCVkeHUh?=
SNU-423NVG0VVVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITibnBKSzVyPUOuNlA{OTNizszNNGnsZmVUSU6JRWK=
A427NXXpNGNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTI[4RpUUN3ME2zMlI2Pjl7IN88US=>MVXTRW5ITVJ?
CAL-12TNEPUSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfLfWhpUUN3ME2zMlQxPzF|IN88US=>M1rzOnNCVkeHUh?=
LU-99AM1LnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjnUJNCUUN3ME2zMlQ4OTB3IN88US=>M3zre3NCVkeHUh?=
MS-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTNwNUO0Nlkh|ryPMkKwV2FPT0WU
SK-LU-1M1fWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEn3bo1KSzVyPUOuO|YzQTVizszNNGLQe3dUSU6JRWK=
SW837M3m3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PSZWlEPTB;Mz63OlM{OyEQvF2=MkjMV2FPT0WU
ES8NGfhdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\QeGlEPTB;Mz64N|g4PyEQvF2=MlXPV2FPT0WU
MZ2-MELMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;UTWM2OD1|LkmyNFg3KM7:TR?=MoDKV2FPT0WU
TGWM1\CNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjTTWM2OD12LkCxN|EyKM7:TR?=MVLTRW5ITVJ?
GP5dM4rmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFryenBKSzVyPUSuNFU{PjJizszNMlPIV2FPT0WU
BB49-HNCM1SzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTLToVmUUN3ME20MlE2OjF|IN88US=>MmTFV2FPT0WU
NB13NXy2TWFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrZTWM2OD12LkK2PFg4KM7:TR?=MmjFV2FPT0WU
NTERA-S-cl-D1M1j0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTRwMki2NVUh|ryPNW\Z[VZ{W0GQR1XS
NCI-H1648MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nR[WlEPTB;ND6yPVgyQSEQvF2=NYPWWo1rW0GQR1XS
LCLC-103HNH\V[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWL4eI1DUUN3ME20MlMzOTl3IN88US=>NX;4emtJW0GQR1XS
LS-411NNVqzUXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7WcGFKSzVyPUSuOFQ5QDVizszNNH7IfpZUSU6JRWK=
NCI-H1092MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPNdFZKSzVyPUSuOFU3QDdizszNNIjoboFUSU6JRWK=
PANC-10-05MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUP3bmN2UUN3ME20MlY6QDRizszNM2DQbnNCVkeHUh?=
DK-MGNH7WcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTRwOEC5N|Mh|ryPM{ewenNCVkeHUh?=
OVCAR-5NHvFZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4j4WmlEPTB;ND64NVIzPiEQvF2=MlG3V2FPT0WU
CAL-39M4TneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPETWM2OD12Lki3Olch|ryPM3zHVXNCVkeHUh?=
TE-441-TNVqwb4ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPEZ|lKSzVyPUSuPVA2OzdizszNMUTTRW5ITVJ?
MOLT-16NX:ybnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGC2V29KSzVyPUSuPVUzPTNizszNMnH5V2FPT0WU
MCF7NUfmZVViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3E[pdKSzVyPUWuNVQ2OTdizszNMoXyV2FPT0WU
CAPAN-1M2XvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HvSGlEPTB;NT6yOVcxPyEQvF2=M2rtfnNCVkeHUh?=
PSN1NHLMdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTVwMkeyN|Uh|ryPMXnTRW5ITVJ?
NCI-H292NWC2e5gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjWTWM2OD13LkOwNFQ1KM7:TR?=NFnH[3FUSU6JRWK=
CPC-NNVftUpJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XtPWlEPTB;NT6zPVQyQSEQvF2=M{Kxd3NCVkeHUh?=
DoTc2-4510NYO2OZR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXDTWM2OD13LkS1N|cyKM7:TR?=NFnYd|VUSU6JRWK=
LB1047-RCCNUSx[FlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjwW|NKSzVyPUWuOVU6OzNizszNNUTJU5J2W0GQR1XS
MHH-ES-1NYOzclBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrKb|R5UUN3ME21MlU6QTB5IN88US=>M4HBN3NCVkeHUh?=
NMC-G1NXX5OJRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIntZZBKSzVyPUWuO|AzOjdizszNM4fiS3NCVkeHUh?=
SW1710MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moq0TWM2OD13Lke0O|UyKM7:TR?=NGLieXVUSU6JRWK=
YAPCMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jMeWlEPTB;NT63OlIxOSEQvF2=MVrTRW5ITVJ?
22RV1MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIC2b2lKSzVyPUWuPFAxOTlizszNNUDoeJZNW0GQR1XS
COLO-679MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\XNGlEPTB;NT64PFk1QCEQvF2=MmfNV2FPT0WU
TCCSUPMm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTVwOUOyOVkh|ryPMXTTRW5ITVJ?
C2BBe1NYDBSJVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHW1fmhKSzVyPUWuPVM6PyEQvF2=MWLTRW5ITVJ?
TE-15M{G0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{mzbWlEPTB;Nj6wOlYxPSEQvF2=MYHTRW5ITVJ?
SCLC-21HMmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\5WJN[UUN3ME22MlExQDR|IN88US=>Mlf1V2FPT0WU
EoL-1-cellNYTDUHlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjCe3hCUUN3ME22MlE3PTZ|IN88US=>NHu4Tm9USU6JRWK=
NKM-1NEHCWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfLTWM2OD14LkG2O|Eh|ryPMUnTRW5ITVJ?
NCI-H1304NFnvZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoOwTWM2OD14LkK3OFI5KM7:TR?=MXHTRW5ITVJ?
NB6M{jOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTZwMkm2NlIh|ryPMkGxV2FPT0WU
NALM-6NGnrdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTZwM{OyN{DPxE1?NHnYbo1USU6JRWK=
NCI-H522M3vvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvCTWM2OD14LkOzN|A3KM7:TR?=NGLZW2RUSU6JRWK=
MV-4-11M4jXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTzTWM2OD14LkO3NFc6KM7:TR?=MlvUV2FPT0WU
LB2241-RCCNUfqWnlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULUOlA4UUN3ME22MlM5PjZ5IN88US=>MmLkV2FPT0WU
NCI-H1417MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3THRmlEPTB;Nj60NFg1PyEQvF2=Mn;SV2FPT0WU
HT-1197NUfMXnY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnoc5VKSzVyPU[uOVcyOjJizszNMUjTRW5ITVJ?
P30-OHKNVjkSmxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTZwNkK3O{DPxE1?NHzGNmdUSU6JRWK=
ALL-POM1T6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUewXI1oUUN3ME22MlcyQTF4IN88US=>M3\vTXNCVkeHUh?=
OVCAR-4MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7YTWM2OD14Lke1OFA2KM7:TR?=Mn3VV2FPT0WU
HCC2157MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTZwN{e0O|Uh|ryPNFriSlhUSU6JRWK=
NCI-H838M1Luemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWe0OW9MUUN3ME22Mlk3PDlizszNNGnSd3FUSU6JRWK=
NCI-H1299Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTZwOUewPUDPxE1?NFvqVGNUSU6JRWK=
SW954NFu3eXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXGRXpKSzVyPUeuNlAxPjhizszNMkDuV2FPT0WU
NCI-H441MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mny5TWM2OD15LkO0NFY2KM7:TR?=MoHxV2FPT0WU
SK-MEL-2MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjYbXE2UUN3ME23MlQ5Ozd|IN88US=>M3;iXnNCVkeHUh?=
KARPAS-45Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojmTWM2OD15Lk[1PVI6KM7:TR?=NX3hRnZRW0GQR1XS
CAL-54MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTdwOEK5O|ch|ryPMn;2V2FPT0WU
KYSE-180MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnI[XVsUUN3ME23Mlg5QTRzIN88US=>NVfIe4lIW0GQR1XS
NCI-H187M4fibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\FT2lKSzVyPUeuPVU6PDdizszNNV3XUVQyW0GQR1XS
RT-112NX3ab45pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRThwMEm2O|ch|ryPM2jXNnNCVkeHUh?=
NCI-H1437M1;oTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7t[GxKSzVyPUiuNFk4QTVizszNMVfTRW5ITVJ?
SNU-449MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojhTWM2OD16LkK4NlczKM7:TR?=M3PKb3NCVkeHUh?=
HCC1187MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkX3TWM2OD16LkK5N|kyKM7:TR?=Ml;QV2FPT0WU
NCI-H2030MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjNZ4VTUUN3ME24MlM4PzF2IN88US=>MYrTRW5ITVJ?
HuO-3N1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHmTWM2OD16LkO3PFQ1KM7:TR?=NVvzTYJEW0GQR1XS
COLO-792NYfSRnVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\xTWM2OD16LkSxOVI4KM7:TR?=NWPmWGlzW0GQR1XS
MIA-PaCa-2MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRThwOEW1NFgh|ryPNUHMeHdGW0GQR1XS
SK-N-FIMlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTlwMESyOUDPxE1?MUfTRW5ITVJ?
MMAC-SFMnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUC0NG96UUN3ME25MlA6PzVzIN88US=>MlXEV2FPT0WU
NCI-H28M1T3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTlwMUC0Olkh|ryPNEPi[pNUSU6JRWK=
ETK-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PVbWlEPTB;OT6yPVk4PCEQvF2=M2exbnNCVkeHUh?=
NCI-H1993MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\PTWM2OD17LkS0NlYyKM7:TR?=NH\TRWxUSU6JRWK=
no-11MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXt[HJKSzVyPUmuOFcyOiEQvF2=NULlVXRIW0GQR1XS
ChaGo-K-1M1;oSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2G0dWlEPTB;OT61NVU5OyEQvF2=MULTRW5ITVJ?
NCCITM{j1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfQTWM2OD17LkWzNVY6KM7:TR?=MVLTRW5ITVJ?
SASMlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrtTWM2OD1zMD6yOFgh|ryPM3[4c3NCVkeHUh?=
A673NEXTNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF:0T3BKSzVyPUGwMlM4ODRizszNNETxN4pUSU6JRWK=
NCI-H1522MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHn3bpdKSzVyPUGwMlM4ODdizszNMlPJV2FPT0WU
NCI-H810MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWraeJZtUUN3ME2xNE4{QTB5IN88US=>MlXjV2FPT0WU
IST-MES1MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTFyLkS1OlQh|ryPMV;TRW5ITVJ?
GR-STNVjCdYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnezTWM2OD1zMD61NFI1KM7:TR?=MYXTRW5ITVJ?
SUP-T1M2LOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHSSWtKSzVyPUGwMlc{OTdizszNMW\TRW5ITVJ?
NB5NV;Yb2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfCeVZQUUN3ME2xNE46ODJ{IN88US=>MnfNV2FPT0WU
MZ1-PCMoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DKT2lEPTB;MUCuPVU4OSEQvF2=MX7TRW5ITVJ?
SK-CO-1NHLZXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTFyLkm5N|Eh|ryPMXrTRW5ITVJ?
Capan-2NFPOcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4j2[2lEPTB;MUGuN|E6QCEQvF2=NGrtRphUSU6JRWK=
697M2jXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fm[WlEPTB;MUGuOlc2PyEQvF2=NH\TVnFUSU6JRWK=
REHM4HMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjtTWM2OD1zMT63OFUyKM7:TR?=MVLTRW5ITVJ?
GI-1NWLHUnA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGi0bVRKSzVyPUGxMlg3OTVizszNMVTTRW5ITVJ?
BB65-RCCMm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjnTWM2OD1zMj6wPVE3KM7:TR?=M1ftUXNCVkeHUh?=
NCI-H1651M{e1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7WOZM2UUN3ME2xNk4zPDd6IN88US=>M{TzXHNCVkeHUh?=
NCI-H1618NIHEVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLwTWM2OD1zMj6zPVc3KM7:TR?=NEjrOmlUSU6JRWK=
NCI-H2081NF\U[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLETWM2OD1zMj62NVQyKM7:TR?=NXWxWI5tW0GQR1XS
GCIYMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkG2TWM2OD1zMj63NlE{KM7:TR?=NEHYSWdUSU6JRWK=
NYNY\QeW1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{K5[WlEPTB;MUOuNFY1OyEQvF2=NXvHVmdJW0GQR1XS
PANC-03-27NWTOfGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2C2NGlEPTB;MUOuNFgxPyEQvF2=NUjLVWM5W0GQR1XS
BHYMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIraRpdKSzVyPUGzMlIyOjFizszNM37KUXNCVkeHUh?=
SK-OV-3NYD3SYl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XJRWlEPTB;MUOuN|c3OyEQvF2=MWrTRW5ITVJ?
5637MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXzeXhZUUN3ME2xN{44PzV7IN88US=>NHy5PGdUSU6JRWK=
LC-1FNEPTPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7YT5pKSzVyPUG0MlA{PTZizszNM2nROXNCVkeHUh?=
SNB75Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2D4bmlEPTB;MUSuNFM5OyEQvF2=M361WHNCVkeHUh?=
CHP-212M1nSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHFZ5FiUUN3ME2xOE4xPDZ2IN88US=>MoThV2FPT0WU
HT-1376M3Pa[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PYbWlEPTB;MUSuNVEzPiEQvF2=M4fQc3NCVkeHUh?=
MONO-MAC-6MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHDXlBZUUN3ME2xOE4yPTB{IN88US=>MoDHV2FPT0WU
CA46M4\lU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTF2LkG4Nlch|ryPM4G2VnNCVkeHUh?=
SCC-15NGPXSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTF2LkW1PFMh|ryPM3HTNnNCVkeHUh?=
ATN-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo[zTWM2OD1zND62OlI4KM7:TR?=M3e4WnNCVkeHUh?=
NCI-H2405M3\2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XxVmlEPTB;MUSuPFE2PyEQvF2=MnSwV2FPT0WU
NCI-H716MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TmS2lEPTB;MUSuPFQ6OyEQvF2=NEO4U29USU6JRWK=
SW620NVL1Rm1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4D3eWlEPTB;MUSuPVAyPCEQvF2=Mm\BV2FPT0WU
NCI-H226Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzjXmRKSzVyPUG0MlkxQDVizszNMnfSV2FPT0WU
SW962NY\tOW9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTF2Lkm0N|Ih|ryPNIrUWpNUSU6JRWK=
KYSE-150MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTF2Lkm1OUDPxE1?M1nk[XNCVkeHUh?=
OCUB-MNUPjSIVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mle5TWM2OD1zND65PFg{KM7:TR?=MXfTRW5ITVJ?
ES7NF;xRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnhe3ZHUUN3ME2xOU4xQTh2IN88US=>MoTCV2FPT0WU
SW1463MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTF3LkSyNlMh|ryPMl;ZV2FPT0WU
CAKI-1NXv5fGNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTF3LkWzOFYh|ryPNYjZ[GNSW0GQR1XS
MKN28M2nk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XzeWlEPTB;MUWuOVQ4QSEQvF2=NFjmPIJUSU6JRWK=
SW13NVPFeYlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLoU2g4UUN3ME2xOU43OThizszNM2\NRnNCVkeHUh?=
A3-KAWNGjrcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;kbodEUUN3ME2xOU46Pjl5IN88US=>Ml3KV2FPT0WU
LU-65NYPFW3kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXWSmRQUUN3ME2xOU46PzZ6IN88US=>NV2wRXJuW0GQR1XS
Calu-1M37ERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTF4LkCzOlgh|ryPMkPHV2FPT0WU
ST486Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLOTWM2OD1zNj6wOFMyKM7:TR?=NFzZUVhUSU6JRWK=
BB30-HNCMmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWL6VYNQUUN3ME2xOk4yOjR4IN88US=>NVnPcWZkW0GQR1XS
EGI-1NX3NbmRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLCTWM2OD1zNj60OFYh|ryPM3e0[XNCVkeHUh?=
SH-4NXjzVlYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXS5bGdwUUN3ME2xOk41PzNzIN88US=>M2DoS3NCVkeHUh?=
MN-60NGP5NFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnixTWM2OD1zNz6yNlk4KM7:TR?=MnXaV2FPT0WU
MPP-89M2fWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rCcGlEPTB;MUeuNlQ2QSEQvF2=NHnJXpdUSU6JRWK=
A2780NWHhSndxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVT5OnFSUUN3ME2xO{41OTN7IN88US=>NXq1d21VW0GQR1XS
DaoyNWi3SlcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnflTWM2OD1zNz60Olk2KM7:TR?=MUfTRW5ITVJ?
NCI-H2126MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTF5LkS3O|Eh|ryPM3TlWnNCVkeHUh?=
NCI-H1563M4DpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTJWoJlUUN3ME2xO{41QTF5IN88US=>Mlj6V2FPT0WU
8-MG-BANXe0WVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTF5Lk[2OFgh|ryPNUPL[JByW0GQR1XS
786-0NFfaRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rTNGlEPTB;MUeuPFM2OyEQvF2=M3iyNXNCVkeHUh?=
AM-38NEjDdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTF5LkmzNFYh|ryPNVL3THhbW0GQR1XS
COLO-824MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LheGlEPTB;MUiuOFQ{PiEQvF2=M2rZR3NCVkeHUh?=
SK-MEL-30MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlL6TWM2OD1zOD61NFgzKM7:TR?=MmXYV2FPT0WU
CESSM4S5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXL0ToJtUUN3ME2xPE44PjB7IN88US=>MXnTRW5ITVJ?
BL-70M1XsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3njZ2lEPTB;MUiuPFE2PiEQvF2=Ml;uV2FPT0WU
NCI-H2170NHXVU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX24cGVKUUN3ME2xPE46OTd7IN88US=>M3y4[nNCVkeHUh?=
HT-3MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTF6Lkm4N{DPxE1?NIjlTlZUSU6JRWK=
BOKUMoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37qb2lEPTB;MUmuNFM5OSEQvF2=M13qVnNCVkeHUh?=
HPAF-IINFjW[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG[1bmRKSzVyPUG5MlMxOTVizszNNUmxfmRQW0GQR1XS
KGNMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TtWWlEPTB;MUmuOFc3PSEQvF2=M1fDOHNCVkeHUh?=
MC-CARNXjubY8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkThTWM2OD1zOT62N|E{KM7:TR?=MmOyV2FPT0WU
BHT-101M1;FZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4SxfmlEPTB;MUmuO|c4KM7:TR?=NF2wPYtUSU6JRWK=
SW1783M3LifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LlXWlEPTB;MUmuO|gxPiEQvF2=NYmxWnJWW0GQR1XS
KP-N-YNMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTJyLkCyOlIh|ryPMV3TRW5ITVJ?
LU-165MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XadmlEPTB;MkCuOVU4OSEQvF2=NInGe2lUSU6JRWK=
GOTOM2H4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkT0TWM2OD1{MD62OFUyKM7:TR?=M4TqcHNCVkeHUh?=
EFM-19NHO4b4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTJzLkC3NVYh|ryPMn21V2FPT0WU
CTV-1MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWC4dWxGUUN3ME2yNU4yODV2IN88US=>M1;HXHNCVkeHUh?=
HELNVHn[VAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTJzLkSyNVYh|ryPMUnTRW5ITVJ?
SNU-C2BNELvdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTJzLkSyOkDPxE1?M1HVZXNCVkeHUh?=
ECC4NHz3U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJzLkewO{DPxE1?MlPnV2FPT0WU
NEC8NFzNOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfmTWM2OD1{MT64N|Y5KM7:TR?=MljBV2FPT0WU
KMOE-2NF:yfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJzLki5NlEh|ryPNWjpXVBEW0GQR1XS
NCI-H524M4j5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfFTWM2OD1{Mj6wPFA5KM7:TR?=MYjTRW5ITVJ?
WSU-NHLMlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTJ{LkG1O|ch|ryPNVK0dm1NW0GQR1XS
SF126M4SyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vZVGlEPTB;MkKuNlQ3QSEQvF2=NEfFNmFUSU6JRWK=
HOP-92NVHoTIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlP5TWM2OD1{Mj6zNVY4KM7:TR?=MoLrV2FPT0WU
CTB-1NIXTfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzXTW1KSzVyPUKyMlQ3PzdizszNNFOwRlRUSU6JRWK=
KYSE-270NEXmVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXSTWM2OD1{Mj65N|U4KM7:TR?=NIL2[|hUSU6JRWK=
SK-MEL-24M2PxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3XfHVKSzVyPUKzMlE5PyEQvF2=M2Xa[3NCVkeHUh?=
Calu-3M4fVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfmZVVKSzVyPUKzMlIyOjhizszNNED3OFhUSU6JRWK=
GAMGNV\wWYxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXSUFhKSzVyPUKzMlI{PjdizszNNUfTWY5qW0GQR1XS
SW1573NG[0bphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJ|Lke0NVUh|ryPMV;TRW5ITVJ?
MHH-NB-11NXLreXVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\BW2lEPTB;MkSuNFE6PCEQvF2=MlPHV2FPT0WU
TK10NEDU[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF[2SldKSzVyPUK0MlUxOTNizszNMkG3V2FPT0WU
LB373-MEL-DNV7XOY4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fPcmlEPTB;MkSuOlA3PCEQvF2=M3O3eXNCVkeHUh?=
KALS-1MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTJ2LkezNlch|ryPMX7TRW5ITVJ?
HUTU-80MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXTbWhKSzVyPUK1MlgxOzJizszNNHLDfZJUSU6JRWK=
HuP-T3NIfMc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPHTWM2OD1{Nj6xOlc1KM7:TR?=Mn\rV2FPT0WU
OE19MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTJ4LkKxOVMh|ryPMlfJV2FPT0WU
J82NYH2TZNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\BbotKSzVyPUK2MlI1PzFizszNM1TBTXNCVkeHUh?=
DU-4475MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mle1TWM2OD1{Nj6zPFE6KM7:TR?=Mo\zV2FPT0WU
DMS-53MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTJ4LkWxN|gh|ryPNUC2eGF3W0GQR1XS
COLO-741NXfGcoFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPaZnRKSzVyPUK2Mlg{PDRizszNMYrTRW5ITVJ?
SW48NYXuSY9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHIVVB3UUN3ME2yOk45QDJizszNMXnTRW5ITVJ?
IGR-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXRTWM2OD1{Nj65N|M1KM7:TR?=MV3TRW5ITVJ?
639-VNFy4bJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4q5[2lEPTB;MkeuNFI1PSEQvF2=MUjTRW5ITVJ?
LK-2MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTGWINFUUN3ME2yO{41OTRzIN88US=>M3zFUHNCVkeHUh?=
NCI-H2347MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrtTWM2OD1{Nz65Olk6KM7:TR?=M2POR3NCVkeHUh?=
NCI-H2228Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnx[pJyUUN3ME2yPE4xQTB3IN88US=>M3LRTnNCVkeHUh?=
LS-123NFHaXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzYTWM2OD1{OD6xNlYzKM7:TR?=NF76XGZUSU6JRWK=
U031NF2xPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\wOXlKSzVyPUK4MlI2OiEQvF2=NXK5SppPW0GQR1XS
NCI-H1792MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\vTWM2OD1{OD60O|IyKM7:TR?=M3PiTHNCVkeHUh?=
NCI-H2087MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTD[Y5kUUN3ME2yPE44PTV{IN88US=>MmP6V2FPT0WU
NCI-H2342NVHjPHZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTJ7LkWyNFgh|ryPMVfTRW5ITVJ?
SW626M2rGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVn4[FlDUUN3ME2yPU44PTZizszNNV\pTYkzW0GQR1XS
LB2518-MELM3vnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nye2lEPTB;MkmuPFE2KM7:TR?=M2KwbnNCVkeHUh?=
RXF393NYnq[2FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7BTWM2OD1|MD6wPVUzKM7:TR?=MlTmV2FPT0WU
LC4-1M3vJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7iTWM2OD1|MD6zNFkzKM7:TR?=NG\K[GRUSU6JRWK=
NCI-H1694MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzvVW5KSzVyPUOwMlY3OjRizszNNULh[5RvW0GQR1XS
K5MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LKcmlEPTB;M{CuPVcxOiEQvF2=M33OdnNCVkeHUh?=
HDLM-2MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3myUmlEPTB;M{CuPVczPSEQvF2=MnnnV2FPT0WU
BCPAPNHzoem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPCTWM2OD1|MT64N|c6KM7:TR?=MVPTRW5ITVJ?
BC-3NHfCXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDFV2hKSzVyPUOyMlE1ODNizszNMX7TRW5ITVJ?
LB996-RCCNFvmfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXj3UHFqUUN3ME2zNk4zOzV6IN88US=>NFzvOW5USU6JRWK=
NCI-H2009Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzLTWM2OD1|Mj60PVgyKM7:TR?=MmjBV2FPT0WU
HTC-C3NYTM[JlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXrfWRYUUN3ME2zN{44PTF7IN88US=>NVHuZ4czW0GQR1XS
LAMA-84M1LQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTN2LkS0NFch|ryPNXvifFNQW0GQR1XS
CCRF-CEMNUXZflVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LFemlEPTB;M{SuOVcyPSEQvF2=NEfldGRUSU6JRWK=
AN3-CAMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLBTWM2OD1|NT6wOVY5KM7:TR?=NEDydotUSU6JRWK=
NCI-H1734NF3PcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTN3LkK1OlEh|ryPMl71V2FPT0WU
Ca-SkiM37Jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXq[3pKSzVyPUO1MlQyODFizszNM2\6WnNCVkeHUh?=
U-266MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGq1PWNKSzVyPUO1MlYyOTRizszNNH\OT4RUSU6JRWK=
SBC-5MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTN3Lke3PFEh|ryPMWTTRW5ITVJ?
GT3TKBMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fTWWlEPTB;M{euNVE2KM7:TR?=M4\McXNCVkeHUh?=
MDA-MB-175-VIIM1PSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX76RVRqUUN3ME2zO{4zOjR6IN88US=>M1rme3NCVkeHUh?=
PFSK-1NXPrdFZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jCbWlEPTB;M{euNlQ{PSEQvF2=NI\ad5RUSU6JRWK=
IMR-5NGHiN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTN5LkK0PFch|ryPM3f5d3NCVkeHUh?=
DaudiNYrHcVF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4q4RmlEPTB;M{euN|U6PyEQvF2=NUPkZ2FqW0GQR1XS
A498MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmT2TWM2OD1|Nz63NlE5KM7:TR?=MorlV2FPT0WU
SCC-4MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjmfGNKSzVyPUO3Mlc5PDNizszNMnvtV2FPT0WU
COLO-680NNYnabGJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\BTWM2OD1|OD6yPFg2KM7:TR?=MnvSV2FPT0WU
SK-MES-1NIfSe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTN6LkOyNVUh|ryPNX21TpNVW0GQR1XS
SRM1\pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HKVWlEPTB;M{iuOVQ6PSEQvF2=NI[zdoZUSU6JRWK=
LNCaP-Clone-FGCNVHyOoJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\ORlZKSzVyPUO4MlU3OzdizszNNWrFRmwzW0GQR1XS
SK-HEP-1M{Ho[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTN6Lke4NlIh|ryPMYLTRW5ITVJ?
BPH-1MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHNOoVjUUN3ME2zPE45OzJ7IN88US=>MWXTRW5ITVJ?
NCI-H1755MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTN7LkW4NVch|ryPNGruOmxUSU6JRWK=
LXF-289NEfrPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHr2blhKSzVyPUO5MlgxQDRizszNM3i2SnNCVkeHUh?=
SW1088MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjTeVBnUUN3ME20NE4zOTB5IN88US=>M4rNXXNCVkeHUh?=
MOLT-4NF;XeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDp[IFNUUN3ME20NE4zQTBzIN88US=>M1zSTXNCVkeHUh?=
AsPC-1NXm0RWhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LxSWlEPTB;NECuOFU5OyEQvF2=MXzTRW5ITVJ?
HOP-62Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEm2WWFKSzVyPUSwMlY2PjhizszNNVz5Wpd1W0GQR1XS
A172M3vCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TM[GlEPTB;NECuPFUyOSEQvF2=NHnjeYlUSU6JRWK=
SN12CM3;0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1j6e2lEPTB;NECuPVM5PSEQvF2=NH;r[VhUSU6JRWK=
MDA-MB-231MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;BSGlEPTB;NECuPVg6QCEQvF2=NYflWm0xW0GQR1XS
RPMI-2650MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTRzLkG1PVMh|ryPNHvSSJhUSU6JRWK=
KYSE-140MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{C3dGlEPTB;NEGuPFEzOyEQvF2=MYrTRW5ITVJ?
KINGS-1MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTR{LkS2PVch|ryPNXe4do5DW0GQR1XS
HSC-3MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlT4TWM2OD12Mj62OlYyKM7:TR?=M3XjfnNCVkeHUh?=
PC-14M3jaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mki4TWM2OD12Mz6xPFgzKM7:TR?=NWjEcHQyW0GQR1XS
COR-L105MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{O5WmlEPTB;NEOuOlUxOiEQvF2=MnrtV2FPT0WU
BE-13MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTR2LkKzO|Eh|ryPMl\XV2FPT0WU
NCI-H661MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\BOWptUUN3ME20OE4zQTV6IN88US=>MWrTRW5ITVJ?
IST-MEL1M2W3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fnNWlEPTB;NESuN|U6QSEQvF2=M{TwWXNCVkeHUh?=
HCC1806NH7QUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPpNnNKSzVyPUS0MlU5PzNizszNNWjPS3hyW0GQR1XS
COLO-800NXraRlVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXXS|lDUUN3ME20OE45PDV|IN88US=>MX3TRW5ITVJ?
IST-SL2Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTMTWM2OD12NT6xNlQ4KM7:TR?=M{f1SHNCVkeHUh?=
8305CNHOzOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\jWJJDUUN3ME20OU4{ODlizszNNGLVOodUSU6JRWK=
UACC-62NFTV[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTR4LkK4O|Uh|ryPNYrQOlhuW0GQR1XS
COR-L23M{TjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\hV2hKSzVyPUS3MlE6QSEQvF2=Mn;mV2FPT0WU
EFE-184NYn2[5hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTaTWM2OD12Nz6zPFgh|ryPMljCV2FPT0WU
DMS-114NEn3[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofKTWM2OD12Nz60NVQ6KM7:TR?=Mn7OV2FPT0WU
KYSE-520MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{e0ZWlEPTB;NEiuOVMyPSEQvF2=MXnTRW5ITVJ?
SNG-MM1nxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\PSmlEPTB;NEmuOFM1KM7:TR?=Mk\SV2FPT0WU
A2058M3;1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DnSmlEPTB;NEmuOFg5PSEQvF2=MkXmV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

Cell Assay: [1]

Cell lines MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
Concentrations 0.02-0.8 μM
Incubation Time 3 days
Method For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

Animal Study: [1]

Animal Models IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
Formulation 25 mM tartaric acid
Dosages 25 mg / kg and 75 mg / kg
Administration Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Mulvihill MJ, et al. Future Med Chem, 2009, 1(6), 1153-1171.

[2] McKinley ET, et al. Clin Cancer Res, 2011, 17(10), 3332-3340.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02057380 Active, not recruiting Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research a  ...more University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2

view more

Chemical Information

Download OSI-906 (Linsitinib) SDF
Molecular Weight (MW) 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

Customer Product Validation(3)


Click to enlarge
Rating
Source Cancer Res 2013 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck
Method Cell proliferation and growth assays
Cell Lines PFR3 cells
Concentrations 1 μM
Incubation Time
Results The IC50 of PFR3 cells for PF299804 was more than 100 fold lower with the combination of OSI-90 than with PF00299804 alone.

Click to enlarge
Rating
Source Cancer Res 2011 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck
Method [18 F]FDG –PET/ Western blot
Cell Lines MCF-7 cells/athymic mice
Concentrations 50 mg/kg/day
Incubation Time 6 weeks
Results mice without palpable tumors were randomized to treatment with vehicle or OSI-906. Six of 20 control mice (30%) developed tumors, whereas none of the 20 OSI-906–treated mice did (Fig. A). OSI-906 inhibited tumor growth compared with vehicle (Fig. B; P < 0.05). OSI-906–treated tumors exhibited markedly lower levels of phosphorylated IGF-IR, InsR, IRS-1, AKT, and S6 compared with vehicle controls (Fig. C). FDG uptake was significantly decreased 4 hours after a single dose of OSI-906 com-pared with baseline (Fig. D)

Click to enlarge
Rating
Source OSI-906 (Linsitinib) purchased from Selleck
Method Flow cytometry/ Western Blotting
Cell Lines CLL B cells
Concentrations 1 µM
Incubation Time 24 h
Results three structurally unrelated IGF1R inhibi tors AG1024, Picropodophyllin (PPP) and linsitinib significantly reduced the cellular viability of primary CLL cells ( Figure A) and reduced levels of phosphorylated IGF1R and IRS-1 (Figure B,C). AG1024, which showed the strongest effect on viability, caused a dose-dependent decrease in the levels of phosphorylated Src, PI3K, Akt, MEK and ERK (Figure D).

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related IGF-1R Products

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • BMS-536924

    BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

  • NVP-AEW541

    NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.

  • NVP-ADW742

    NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

  • GSK1904529A

    GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.

  • BMS-754807

    BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

    Features:Muti-inhibitor of the IGR-1R/IR family.

  • AG-1024

    AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).

  • PQ 401

    PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Recently Viewed Items

Tags: buy OSI-906 (Linsitinib) | OSI-906 (Linsitinib) supplier | purchase OSI-906 (Linsitinib) | OSI-906 (Linsitinib) cost | OSI-906 (Linsitinib) manufacturer | order OSI-906 (Linsitinib) | OSI-906 (Linsitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us